Denali Therapeutics Inc.
Denali Therapeutics Inc. (DNLI) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Denali Therapeutics Inc. (DNLI), covering cash flow, earnings, and balance sheets.
Denali Therapeutics Inc. (DNLI) Income Statement & Financial Overview
Review Denali Therapeutics Inc. DNLI income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $1.94M |
| Gross Profit | $0.00 | $0.00 | $0.00 | -$1.94M |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $116.23M | $99.79M | $98.24M | $91.40M |
| SG&A Expenses | $29.35M | $30.06M | $24.95M | $23.25M |
| Operating Expenses | $145.58M | $129.85M | $123.19M | $114.65M |
| Total Costs & Expenses | $145.58M | $138.05M | $123.19M | $116.59M |
| Interest Income | $12.61M | $15.16M | $15.99M | $17.57M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $3.21M | $2.62M | $2.27M | $1.94M |
| EBITDA | -$142.37M | -$127.23M | -$120.92M | -$114.65M |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$145.58M | -$129.85M | -$123.19M | -$116.59M |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $12.61M | $15.16M | $15.99M | $17.57M |
| Income Before Tax | -$132.97M | -$114.69M | -$107.19M | -$99.03M |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $0.00 | $68000.00 | $0.00 | $0.00 |
| Net Income | -$132.97M | -$114.75M | -$107.19M | -$99.03M |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$0.78 | -$0.67 | -$0.63 | -$0.59 |
| Diluted EPS | -$0.78 | -$0.67 | -$0.63 | -$0.59 |
| Weighted Avg Shares Outstanding | $171.22M | $170.09M | $169.46M | $168.83M |
| Weighted Avg Shares Outstanding (Diluted) | $171.22M | $170.09M | $169.46M | $168.83M |
Over the last four quarters, Denali Therapeutics Inc.'s revenue moved from $0.00 in Q2 2024 to $0.00 in Q1 2025. Operating income in Q1 2025 was -$145.58M, with a strong operating margin of N/A. Despite fluctuations in R&D and SG&A expenses, EBITDA for Denali Therapeutics Inc. remained robust at -$142.37M, reflecting operational efficiency. Net income dropped to -$132.97M, with an EPS of -$0.78. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan